Several brokerages have updated their recommendations and price targets on shares of Globus Medical (NYSE: GMED) in the last few weeks:
- 5/9/2026 – Globus Medical was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 5/8/2026 – Globus Medical had its price target lowered by Wells Fargo & Company from $104.00 to $103.00. They now have an “overweight” rating on the stock.
- 5/8/2026 – Globus Medical had its price target raised by Royal Bank Of Canada from $115.00 to $120.00. They now have an “outperform” rating on the stock.
- 5/8/2026 – Globus Medical had its price target raised by Needham & Company LLC from $114.00 to $117.00. They now have a “buy” rating on the stock.
- 4/15/2026 – Globus Medical had its “hold (c+)” rating reaffirmed by Weiss Ratings.
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Featured Stories
- Five stocks we like better than Globus Medical
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
- Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity
- 3 Stocks Under $40 with Indirect Exposure to SpaceX IPO
Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.
